Webinars and Sponsored Roundtables — Register Now
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
Werfen
| Company | Werfen |
|---|---|
| Instrument name | ACL TOP 550 CTS |
| Contact | Annie Lopatin |
| City State | Bedford, MA |
| Phone | 800-955-9525 |
| Website | |
| First year sold | 2016 |
| List price/Model type | —/benchtop |
| Dimensions (H × W × D)/Weight/Instrument footprint | 29 × 43 × 35 in./312 lbs./14 sq. ft. |
| No. of units in clinical use in U.S./Outside U.S. | 737/3, 400 (available in most countries) |
| Composition of installs: Hospital lab/Reference lab/Other | 85%/12%/3% (pharmaceutical or medical device labs) |
| Targeted daily, monthly, annual test volume | daily: 100–200; monthly: 3, 000–6, 000; annual: 36, 000–72, 000 |
| Operational type | random access |
| Country where analyzer designed/Manufactured | U.S./U.S. |
| Company manufactures instrument | yes |
| FDA-approved clotting-based tests | PT, APTT, fibrinogen, thrombin time, factor assays, lupus anticoagulant (dRVVT and silica clotting time), protein S, protein C |
| FDA-approved chromogenic tests | anti-Xa, apixaban, protein C, antithrombin, plasminogen, plasmin inhibitor |
| FDA-approved immunologic tests | high specificity D-dimer, standard D-dimer, heparin-induced thrombocytopenia, von Willebrand factor antigen, von Willebrand factor activity, free protein S, factor XIII antigen, homocysteine |
| Other FDA-approved tests | — |
| User-defined tests in clinical use | DOAC assays, chromogenic factor VIII |
| Tests in development or awaiting FDA 510(k) clearance | von Willebrand factor ristocetin cofactor, dabigatran, rivaroxaban, apixaban |
| Methodologies supported | clot detection, optical; chromogenic; immunologic (immunoturbidimetric) |
| Number of different measured assays onboard simultaneously | 30 |
| Number of different assays programmed and calib. at one time | 500 |
| No. of user-definable (open) channels/No. active simultaneously | 250/250 |
| Factor assays require manual manipulation or dilutions | — |
| Test throughput per hour/Assay run time | 240 (1 test in throughput)/3–6 min. (avg. 4 min.) |
| Design of sample-handling system | samples loaded into rack; integrated sample barcode reader eliminates any post-draw sample misidentification |
| Operates on whole blood or spun plasma | spun plasma |
| Reagent type | self-contained multiuse vials; open reagent system (liquid, lyophilized [reconstituted manually]) |
| Reagent barcode-reading capability | yes, for all tests |
| No. of reagent containers held onboard/Reagents ready to use | 40/variable (reagent specific) |
| Reagent lot tracking/Reagent inventory/Reagents refrigerated onboard | yes/yes/yes |
| Reagents, consumables loaded without interrupting testing | yes (reagents and consumables) |
| Instrument uses proprietary or third-party reagents | user’s option (same capabilities when third-party reagents used) |
| Maximum time same lot number of reagents can be used | — |
| Walkaway capability/Walkaway duration | yes/80 specimens or 800 tests |
| Min.–max. specimen volume that can be aspirated at one time | 2–250 µL |
| Min. sample volume required for PT/PTT/Factor VIII activity | 50 µL/50 µL/50 µL |
| Types of disposables used | cuvettes, clean A/B, rinse |
| Primary tube sampling supported/Pierces caps on primary tubes | yes/yes |
| Accommodates most standard tube sizes/Nonstandard sizes | yes/yes |
| Sample barcode-reading capability/Autodiscrimination | yes (Interleaved 2 of 5, Code 39, Code 128)/yes |
| Auto tracks product volume/Measures number of tests remaining | yes/yes |
| Short sample detection | yes |
| Clot detection as preanalytical variable in plasma sample | yes |
| Auto detects adequate reagents for aspiration or analysis | yes (aspiration and analysis) |
| Detection or quantitation for hemolysis, turbidity, icterus, lipemia | detection and quantitation for hemolysis, turbidity, icterus, lipemia |
| Dilutes patient samples onboard | yes |
| Automatic rerun capability/Auto reflex testing capability | yes/yes |
| Lag time during which hypercoagulable sample not detected | no |
| User can adjust reagent volumes/Sample volumes | yes/yes |
| User can adjust No. of reagents/Sources of reagents | yes/yes |
| User can adjust incubation times/Reading times | yes/yes |
| Autocalibration/Calibrants stored onboard | no/no |
| Multipoint calibration supported/Recommended frequency | yes/per lab’s quality management system rules |
| • PT alone | <3 minutes/240 specimens |
| • PT, PTT | <6 minutes/90 specimens |
| • Fibrinogen | <3 minutes/78 specimens |
| • Factor VIII activity assay | 8 minutes/77 specimens |
| • D-dimer | 5 minutes/75 specimens |
| Time delay from ordering stat to aspiration of sample | none |
| How labs get LOINC codes for results | functionality not provided |
| Onboard real-time QC/Onboard software capability to review QC | yes/yes |
| Information that can be barcode-scanned on instrument | specimen identifier, reagent lot No., International Sensitivity Index |
| Compatible with laboratory automation systems | no |
| Data-management capability/LIS or EHR systems interfaced | onboard/Oracle Health, CompuLab, CPSI, HBOC, HMS, McKesson, Meditech, Novius, SMS, SCC, Clinisys, Vista |
| Interface supplied by instrument vendor | contract dependent |
| Results transferred to LIS as soon as test time complete | yes |
| Bidirectional interface capability | yes (broadcast download and host query) |
| Remote servicing provided/UPS backup power supply | yes/yes |
| Instrument connections to transfer information | data-management system, which in turn connects to LIS; directly to LIS; commercial middleware (Beckman Coulter) |
| Interface standards supported | ASTM 1394-91 |
| Information transferred to data-management software | specimen ID |
| Avg. time for basic user training | 14 days (10 days at customer site, 4 days at vendor office) |
| Approximate scheduled maintenance time | daily: 5 minutes; weekly: 10 minutes |
| Maintenance records kept onboard | yes |
| Warranty with purchase/Annual service contract cost (24/7) | yes/— (cost dependent on contract) |
| Distinguishing features (supplied by company) | FDA 510(k) approved; improves patient care, lab efficiencies, and costs; supports lab’s policy on sample acceptance with quantitative HIL, sample fill detection, aspiration errors (clots); liquid format for PT/APTT (10-day onboard stability), high specificity D-dimer, on-demand heparin-induced thrombocytopenia testing |